Enterome vs Forlong Biotechnology
Enterome vs Forlong Biotechnology, compared side by side on 13 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Enterome is on 60/100 and Forlong Biotechnology on 42/100.
Where each one leads
Enterome
- our overall score: 60/100 against 42/100
- funding raised: $124M against $22.5M
Forlong Biotechnology
Leads on none of the measures we hold for both companies.
At a glance
| Measure | Enterome | Forlong Biotechnology |
|---|---|---|
| What it is | Clinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases. | Clinical-stage biotech company developing transformative cytokine therapies. |
| Category | Biotechnology, Drug Discovery, Oncology, Immunotherapy | Biotechnology, Pharmaceuticals, Healthcare, Biotech |
| Sells toBusiness model | B2B | B2B |
| Offering | Software | hardware | services | marketplace | platform | Services |
| Founded | 2012 | Not published |
| Headquarters | Paris, France | Shanghai, China |
| Status | Active | Inactive |
Size, funding and growth
| Measure | Enterome | Forlong Biotechnology |
|---|---|---|
| Employees | 33 | Not published |
| Total funding | $124M | $22.5M |
| Latest round | Later Stage VC | Series Pre-B |
| LinkedIn followers | 16,846 | Not published |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | Enterome | Forlong Biotechnology |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 60/100 | 42/100 |
| Traction | 55/100 | 37/100 |
| Team | 70/100 | Not published |
| Search visibility | 34/100 | 12/100 |
| Quality | 68/100 | 58/100 |
| Agent readinessHow well an AI agent can read and act on the site | F (21/100) | F (21/100) |
| Domain ratingLink authority, 0-100 | 46/100 | Not published |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | Enterome | Forlong Biotechnology |
|---|---|---|
| Hosting | Self Managed | Not detected |
| CMS | WordPress | Not detected |
| Frameworks | Bootstrap | Not detected |
| Analytics | Google Analytics 4, Segment | Not detected |
Enterome vs Forlong Biotechnology: common questions
Which is better, Enterome or Forlong Biotechnology?
On our 0-100 score Enterome rates higher (60/100 against 42/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 13 data points above: read the rows that match what you are buying for.
How do Enterome and Forlong Biotechnology compare on the numbers?
Enterome leads on our overall score (60/100 against 42/100), funding raised ($124M against $22.5M).
Read the full Enterome review and pricing or the Forlong Biotechnology review and pricing. You can also browse other Enterome alternatives we track.